-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pharmaceutical company Novavax today announced that its protein -based COVID-19 vaccine, NVX-CoV2373, demonstrated near 80% efficacy in adolescent participants in the pivotal PREVENT-19 trial
.
The company expects to file for regulatory approval in the first quarter and plans to launch more studies to evaluate younger cohorts by the end of June
Pharmaceutical company Novavax today announced that its protein -based COVID-19 vaccine, NVX-CoV2373, demonstrated near 80% efficacy in adolescent participants in the pivotal PREVENT-19 trial
Novavax said its vaccine had an overall protection rate of 79.
5% against COVID-19 in this young cohort and met its primary efficacy endpoint, with neutralizing antibody responses that were non-inferior to those of 18- to 26-year-old adults participating in the trial
.
Efficacy was consistent across age groups in the adolescent cohort, and all cases in the vaccine group were mild, Novavax said
The company noted that efficacy was evaluated between the end of May and the end of September 2021, when the Delta mutant was the predominant strain circulating in the United States
.
In a post-hoc analysis, Novavax said its vaccine elicited a "robust" immune response in adolescents, with IgG responses to several variants of the Spike protein, including Omicron, two to three times higher than in adults after the two-dose series
.
In addition, the company said functional immune responses against these variants were 2.
immunity
At the same time, Novavax said preliminary safety data showed that the vaccine was generally well-tolerated, with a low rate of serious adverse events and was not considered to be related to the vaccine
.
The incidence of adverse reactions was similar in the NVX-CoV2373 and placebo groups
Original source:
Original source:https://firstwordpharma.
https://firstwordpharma.
com/story/5497393 https://firstwordpharma.
com/story/5497393 Leave a comment here
